Novel antibacterial protein efal-2 having bacteriolytic ability with respect to enterococcus faecium

Abstract

The present invention relates to an antibacterial protein EFAL-2 derived from bacteriophage Ent-FAP-4 (deposition number KCTC 12854BP), a pharmaceutical composition including the same as an active ingredient, and a method for preventing or treating diseases caused by Enterococcus faecium by using the pharmaceutical composition, the antibacterial protein EFAL-2 being characterized by having the ability capable of killing Enterococcus faecium and having an amino acid sequence represented by SEQ ID NO: 2.

1 . An antibacterial protein EFAL-2 which has bacteriolytic ability against  Enterococcus faecium  and an amino acid sequence represented by SEQ ID NO: 1. 
     
     
         2 . The antibacterial protein EFAL-2 of  claim 1 , wherein the antibacterial protein EFAL-2 is derived from bacteriophage Ent-FAP-4 (Accession number: KCTC 12854BP). 
     
     
         3 . A gene for coding the antibacterial protein EFAL-2 of  claim 1 . 
     
     
         4 . The gene of  claim 3 , wherein the gene has a nucleotide sequence represented by SEQ ID NO: 1. 
     
     
         5 . An  Escherichia coli  transformant TOP10-pBAD-EFAL-2 (Accession number: KCTC 13177BP) used for production of the antibacterial protein EFAL-2 of  claim 1 . 
     
     
         6 . A method for manufacturing the antibacterial protein EFAL-2 of  claim 1  using  Escherichia coli  TOP10-pBAD-EFAL-2 (Accession number: KCTC 13177BP). 
     
     
         7 . A pharmaceutical composition for preventing or treating diseases caused by  Enterococcus faecium , the pharmaceutical composition comprising: the antibacterial protein EFAL-2 of  claim 1  as an active ingredient. 
     
     
         8 . The pharmaceutical composition of  claim 7 , wherein the pharmaceutical composition is used in a form of a pharmaceutical composition further containing an antibiotic. 
     
     
         9 . A method for preventing or treating diseases caused by  Enterococcus faecium , the method comprising:
 administering the pharmaceutical composition of  claim 7  to a subject to be treated.   
     
     
         10 . The method of  claim 9 , wherein the pharmaceutical composition is administered in a form of a pharmaceutical composition containing an antibiotic to the subject to be treated.